Table 1.
In vitro anticancer activities of compounds 1–24 against U 87, SMMC-7721, SGC-7901, MGC-803 cell lines.
| Compounds | IC50 μM (n = 3) |
||||
|---|---|---|---|---|---|
| U87 | SMMC-7721 | SGC-7901 | MGC-803 | L02 | |
| 1 | – | – | – | – | –a |
| 2 | – | – | – | – | – |
| 3 | 8.0 ± 0.85 | 15.6 ± 3.3 | 10.6 ± 4.3 | 4.5 ± 1.1 | 13.6 ± 1.5 |
| 4 | 65.7 ± 2.7 | 75.1 ± 0.4 | – | – | |
| 5 | – | – | – | – | – |
| 6 | – | – | – | – | – |
| 7 | 9.68 ± 2.3 | 14.4 ± 1.5 | 33.6 ± 2.1 | 9.7 ± 2.3 | 36.8 ± 4.1 |
| 8 | 10.0 ± 1.6 | 16.7 ± 1.8 | 20 ± 3.9 | 10.4 ± 0.7 | >50 |
| 9 | 4.45 ± 0.66 | 12.3 ± 0.1 | 8.6 ± 2.5 | 3.1 ± 0.1 | 12.1 ± 0.8 |
| 10 | 12.3 ± 2.8 | 12.4 ± 2.6 | 11.1 ± 1.2 | 7.9 ± 1.8 | 11.9 ± 0.6 |
| 11 | 3.75 ± 0.77 | 9.5 ± 0.8 | 2.25 ± 1.5 | 8.4 ± 3.1 | 4.0 ± 0.1 |
| 12 | 3.8 ± 0.2 | 20.6 ± 0.4 | 4.1 ± 2.6 | 4.1 ± 0.6 | >50 |
| 13 | 3.46 ± 0.31 | 16.9 ± 2.2 | 7.8 ± 3.7 | 10.2 ± 2.9 | 15.8 ± 1.1 |
| 14 | – | 14.8 ± 0.1 | 10.7 ± 1.8 | 10.2 ± 1.3 | 16.2 ± 1.7 |
| 15 | – | – | – | – | – |
| 16 | 5.41 ± 0.67 | 24.3 ± 1.7 | 5.6 ± 2.6 | 5.9 ± 2.6 | 13.0 ± 2.4 |
| 17 | 3.8 ± 1.7 | 15.9 ± 0.2 | 20.8 ± 0.5 | 6.7 ± 2.4 | 11.4 ± 1.8 |
| 18 | 7.7 ± 4.4 | 17.9 ± 1.6 | 23.7 ± 0.5 | 6.6 ± 4.7 | 20.2 ± 2.0 |
| 19 | 9.1 ± 2.5 | 17.9 ± 1.0 | 7.6 ± 2.3 | 5.7 ± 2.4 | 8.5 ± 0.4 |
| 20 | 5.2 ± 1.4 | 18.6 ± 3.6 | 13.3 ± 0.6 | 3.5 ± 1.4 | 12.3 ± 0.5 |
| 21 | 6.1 ± 0.6 | 15.4 ± 0.4 | 14.8 ± 1.6 | 6.9 ± 3.9 | 16.0 ± 2.2 |
| 22 | 40.7 ± 4.7 | 46.5 ± 1.7 | 19.8 ± 1.8 | 9.4 ± 0.4 | >50 |
| 23 | – | – | – | – | – |
| 24 | 20.6 ± 0.6 | 50.1 ± 0.8 | 38.5 ± 0.7 | 40.8 ± 1.9 | – |
| ADM | 0.57 ± 0.32 | 0.46 ± 0.63 | 0.72 ± 0.12 | 0.48 ± 0.06 | – |
aInactive at 100 µM (highest concentration tested).